Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2007

01-06-2007 | PRECLINICAL STUDY

Hypoxia-inducible factor-1α correlates with MET and metastasis in node-negative breast cancer

Authors: Helen H. W. Chen, Wu-Chou Su, Pin-Wen Lin, How-Ran Guo, Wen-Ying Lee

Published in: Breast Cancer Research and Treatment | Issue 2/2007

Login to get access

Summary

The mechanism of tumor hypoxia promoting metastasis remains uncertain. Hypoxia-inducible factor-1α (HIF-1α) is a key mediator of the cellular response to hypoxia and binds the met promoter, resulting in increased expression of MET. In breast cancer, MET overexpression is associated with death caused by metastatic disease. Aim of this study is to investigate the role of HIF-1α in MET expression and metastasis in lymph node negative breast cancer. We recruited a homogeneous cohort of 104 patients with T1–2N0M0 breast carcinoma, who had undergone primary surgery. Fifty-three patients had distant metastases and 51 patients had no evidence of disease for more than 10 years. We analyzed the expressions of HIF-1α and MET in these patients using immunohistochemistry. HIF-1α and MET were positively correlated (Spearman’s rank correlation coefficient, 0.35; P < 0.01), were independent predictors of distant metastasis (P = 0.002 and P = 0.03, respectively), and correlated with poor 10-year disease-free survival rate (P < 0.001 for both). Furthermore, co-overexpression of HIF-1α and MET was a significant independent predictor of distant metastasis (odd radio, 10.78; P < 0.001), and patients with co-overexpression had a significantly worse 10-year disease-free survival rate. The results provide evidence that tumor hypoxia promotes metastasis through the induction of MET overexpression by HIF-1α and emphasize the promising status of HIF-1α as a therapeutic target against metastasis in node-negative breast cancer.
Literature
1.
go back to reference Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58:1408–1416PubMed Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58:1408–1416PubMed
2.
go back to reference Höckel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266–276PubMedCrossRef Höckel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266–276PubMedCrossRef
3.
go back to reference Dachs GU, Chaplin DJ (1998) Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis. Semin Radiat Oncol 8:208–216PubMedCrossRef Dachs GU, Chaplin DJ (1998) Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis. Semin Radiat Oncol 8:208–216PubMedCrossRef
4.
go back to reference Höckel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509–4515PubMed Höckel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56:4509–4515PubMed
5.
go back to reference Höckel M, Schlenger K, Höckel S, Vaupel P (1999) Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 59:4525–4528PubMed Höckel M, Schlenger K, Höckel S, Vaupel P (1999) Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 59:4525–4528PubMed
6.
go back to reference Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92:5510–5514PubMedCrossRef Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92:5510–5514PubMedCrossRef
7.
go back to reference Semenza GL (1999) Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15:551–578PubMedCrossRef Semenza GL (1999) Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15:551–578PubMedCrossRef
8.
go back to reference Gopfert T, Gess B, Eckardt KU, Kurtz A (1996) Hypoxia signalling in the control of erythropoietin gene expression in rat hepatocytes. J Cell Physiol 168:354–361PubMedCrossRef Gopfert T, Gess B, Eckardt KU, Kurtz A (1996) Hypoxia signalling in the control of erythropoietin gene expression in rat hepatocytes. J Cell Physiol 168:354–361PubMedCrossRef
9.
go back to reference Takagi H, King GL, Aiello LP (1998) Hypoxia upregulates glucose transport activity through an adenosine-mediated increase of GLUT1 expression in retinal capillary endothelial cells. Diabetes 47:1480–1488PubMedCrossRef Takagi H, King GL, Aiello LP (1998) Hypoxia upregulates glucose transport activity through an adenosine-mediated increase of GLUT1 expression in retinal capillary endothelial cells. Diabetes 47:1480–1488PubMedCrossRef
10.
go back to reference Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604–4613PubMed Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604–4613PubMed
11.
go back to reference Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830–5835PubMed Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830–5835PubMed
12.
go back to reference Bos R, Zhong H, Hanrahan CF, Mommers ECM, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E (2001) Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst 93:309–314PubMedCrossRef Bos R, Zhong H, Hanrahan CF, Mommers ECM, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E (2001) Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst 93:309–314PubMedCrossRef
13.
go back to reference Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G (2002) Overexpression of Hypoxia-inducible factor 1α is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8:1831–1837PubMed Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G (2002) Overexpression of Hypoxia-inducible factor 1α is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8:1831–1837PubMed
14.
go back to reference Gruber G, Greiner RH, Hlushchuk R, Aebersold DM, Altermatt HJ, Berclaz G, Djonov V (2004) Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res 6:R191–R198PubMedCrossRef Gruber G, Greiner RH, Hlushchuk R, Aebersold DM, Altermatt HJ, Berclaz G, Djonov V (2004) Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res 6:R191–R198PubMedCrossRef
15.
go back to reference Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97:1573–1581PubMedCrossRef Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97:1573–1581PubMedCrossRef
16.
go back to reference Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P, Charpin C (2005) Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 116:734–739PubMedCrossRef Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P, Charpin C (2005) Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 116:734–739PubMedCrossRef
17.
go back to reference Rofstad EK, Rasmussen H, Galappathi K, Mathiesen B, Nilsen K, Graff BA (2002) Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res 62:1847–1853PubMed Rofstad EK, Rasmussen H, Galappathi K, Mathiesen B, Nilsen K, Graff BA (2002) Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res 62:1847–1853PubMed
18.
19.
go back to reference Vande Woude GF, Jeffers M, Cortner J, Alvord G, Tsarfaty I, Resau J (1997) Met-HGF/SF: tumorigenesis, invasion and metastasis. Ciba Found Symp 212:119–130PubMed Vande Woude GF, Jeffers M, Cortner J, Alvord G, Tsarfaty I, Resau J (1997) Met-HGF/SF: tumorigenesis, invasion and metastasis. Ciba Found Symp 212:119–130PubMed
20.
go back to reference Ghoussoub RA, Dillon DA, D’Aquila T, Rimm EB, Fearon ER, Rimm DL (1998) Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82:1513–1520PubMedCrossRef Ghoussoub RA, Dillon DA, D’Aquila T, Rimm EB, Fearon ER, Rimm DL (1998) Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82:1513–1520PubMedCrossRef
21.
go back to reference Camp RL, Rimm EB, Rimm DL (1999) Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86:2259–2265PubMedCrossRef Camp RL, Rimm EB, Rimm DL (1999) Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86:2259–2265PubMedCrossRef
22.
go back to reference Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR (2005) Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 11:2222–2228PubMedCrossRef Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR (2005) Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 11:2222–2228PubMedCrossRef
23.
go back to reference Nagy J, Clark JS, Cooke A, Campbell AM, Connor JM, Purushotham AD, George WD (1995) Expression and loss of heterozygosity of c-met proto-oncogene in primary breast cancer. J Surg Oncol 60:95–99PubMedCrossRef Nagy J, Clark JS, Cooke A, Campbell AM, Connor JM, Purushotham AD, George WD (1995) Expression and loss of heterozygosity of c-met proto-oncogene in primary breast cancer. J Surg Oncol 60:95–99PubMedCrossRef
24.
go back to reference Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347–361PubMedCrossRef Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347–361PubMedCrossRef
25.
go back to reference Hayashi M, Sakata M, Takeda T, Tahara M, Yamamoto T, Okamoto Y, Minekawa R, Isobe A, Ohmichi M, Tasaka K, Murata Y (2005) Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1α is involved in trophoblast invasion under low-oxygen tension. Endocrinology 146:4682–4689PubMedCrossRef Hayashi M, Sakata M, Takeda T, Tahara M, Yamamoto T, Okamoto Y, Minekawa R, Isobe A, Ohmichi M, Tasaka K, Murata Y (2005) Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1α is involved in trophoblast invasion under low-oxygen tension. Endocrinology 146:4682–4689PubMedCrossRef
26.
go back to reference Scarpino S, Cancellario d’Alena F, Di Napoli A, Pasquini A, Marzullo A (2004) Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol 202:352–358PubMedCrossRef Scarpino S, Cancellario d’Alena F, Di Napoli A, Pasquini A, Marzullo A (2004) Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol 202:352–358PubMedCrossRef
27.
go back to reference Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD (1995) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87:1441–1445PubMedCrossRef Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD (1995) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87:1441–1445PubMedCrossRef
28.
go back to reference Hasebe T, Tsuda H, Hirohashi S, Shimosato Y, Tsubono Y, Yamamoto H, Mukai K (1998) Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat 49:195–208PubMedCrossRef Hasebe T, Tsuda H, Hirohashi S, Shimosato Y, Tsubono Y, Yamamoto H, Mukai K (1998) Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat 49:195–208PubMedCrossRef
29.
go back to reference Colpaert C, Vermeulen P, Jeuris W, van Beest P, Goovaerts G, Weyler J, Van Dam P, Dirix L, Van Marck E (2001) Early distant relapse in “node-negative” breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J Pathol 193:442–449PubMedCrossRef Colpaert C, Vermeulen P, Jeuris W, van Beest P, Goovaerts G, Weyler J, Van Dam P, Dirix L, Van Marck E (2001) Early distant relapse in “node-negative” breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J Pathol 193:442–449PubMedCrossRef
30.
go back to reference Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G (2002) Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8:1831–1837PubMed Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G (2002) Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8:1831–1837PubMed
31.
go back to reference Ghoussoub RA, Dillon DA, D’Aquila T, Rimm EB, Fearon ER, Rimm DL (1998) Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82:1513–1520PubMedCrossRef Ghoussoub RA, Dillon DA, D’Aquila T, Rimm EB, Fearon ER, Rimm DL (1998) Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82:1513–1520PubMedCrossRef
32.
go back to reference Kallinowski F, Zander R, Hoeckel M, Vaupel P (1990) Tumor tissue oxygenation as evaluated by computerized pO2-histography. Int J Radiat Oncol Biol Phys 19:953–961PubMed Kallinowski F, Zander R, Hoeckel M, Vaupel P (1990) Tumor tissue oxygenation as evaluated by computerized pO2-histography. Int J Radiat Oncol Biol Phys 19:953–961PubMed
33.
34.
go back to reference Colpaert C, Vermeulen P, van Beest P, Goovaerts G, Weyler J, Van Dam P, Dirix L, Van Marck E (2001) Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology 39:416–425PubMedCrossRef Colpaert C, Vermeulen P, van Beest P, Goovaerts G, Weyler J, Van Dam P, Dirix L, Van Marck E (2001) Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology 39:416–425PubMedCrossRef
35.
go back to reference Gilchrist KW, Gray R, Fowble B, Tormey DC, Taylor SG IV (1993) Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node positive breast cancer: a 10 year follow-up study of 728 eastern cooperative oncology group patients. J Clin Oncol 11:1929–1935PubMed Gilchrist KW, Gray R, Fowble B, Tormey DC, Taylor SG IV (1993) Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node positive breast cancer: a 10 year follow-up study of 728 eastern cooperative oncology group patients. J Clin Oncol 11:1929–1935PubMed
36.
go back to reference Dewhirst MW (1998) Concepts of oxygen transport at the microcirculatory level. Semin Radiat Oncol 8:143–150PubMedCrossRef Dewhirst MW (1998) Concepts of oxygen transport at the microcirculatory level. Semin Radiat Oncol 8:143–150PubMedCrossRef
37.
go back to reference Ramanujan S, Koenig GC, Padera TP, Stoll BR, Jain RK (2000) Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. Cancer Res 60:1442–1448PubMed Ramanujan S, Koenig GC, Padera TP, Stoll BR, Jain RK (2000) Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. Cancer Res 60:1442–1448PubMed
38.
go back to reference Tomes L, Emberley E, Niu Y, Troup S, Pastorek J, Strange K, Harris A, Watson PH (2003) Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res Treat 81:61–69PubMedCrossRef Tomes L, Emberley E, Niu Y, Troup S, Pastorek J, Strange K, Harris A, Watson PH (2003) Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res Treat 81:61–69PubMedCrossRef
39.
40.
go back to reference Powell ME, Collingridge DR, Saunders MI, Hoskin PJ, Hill SA, Chaplin DJ (1999) Improvement in human tumour oxygenation with carbogen of varying carb concentrations. Radiother Oncol 50:167–171PubMedCrossRef Powell ME, Collingridge DR, Saunders MI, Hoskin PJ, Hill SA, Chaplin DJ (1999) Improvement in human tumour oxygenation with carbogen of varying carb concentrations. Radiother Oncol 50:167–171PubMedCrossRef
41.
go back to reference Stratford IJ, Workman P (1998) Bioreductive drugs into the nest millennium. Ant Cancer Drug Design 13:519–528 Stratford IJ, Workman P (1998) Bioreductive drugs into the nest millennium. Ant Cancer Drug Design 13:519–528
42.
go back to reference Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KMS, Stratford IJ, Harris AL (1997) Targeting gene expression to hypoxic tumor cell. Nat Med 3:515–520PubMedCrossRef Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KMS, Stratford IJ, Harris AL (1997) Targeting gene expression to hypoxic tumor cell. Nat Med 3:515–520PubMedCrossRef
Metadata
Title
Hypoxia-inducible factor-1α correlates with MET and metastasis in node-negative breast cancer
Authors
Helen H. W. Chen
Wu-Chou Su
Pin-Wen Lin
How-Ran Guo
Wen-Ying Lee
Publication date
01-06-2007
Published in
Breast Cancer Research and Treatment / Issue 2/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9360-3

Other articles of this Issue 2/2007

Breast Cancer Research and Treatment 2/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine